Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447118 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
A Phase 3 study, sponsored by Jiangsu HengRui Medicine Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
NCT04447118 is a Phase 3 study that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 151 participants.
The verdict
NCT04447118, a Phase 3 study, has completed, sponsored by Jiangsu HengRui Medicine Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
Study Summary
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Pyrotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2024-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447118
The ClinicalTrials.gov registry entry for NCT04447118 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT04447118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04447118 about?
NCT04447118 is a clinical study titled "Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy". This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
What is the current status of trial NCT04447118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2020-09-11. Estimated completion is 2024-12-06.
What interventions are being tested in trial NCT04447118?
The interventions under investigation include: Docetaxel (DRUG), Pyrotinib (DRUG).
Who is sponsoring clinical trial NCT04447118?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.